Please use this identifier to cite or link to this item:
Title: Population Pharmacokinetics of Polymyxin B
Authors: Pooja Manchandani
Visanu Thamlikitkul
Yanina Dubrovskaya
Jessica T. Babic
David C. Lye
Lawrence S. Lee
Vincent H. Tam
NYU Langone Medical Center
Yong Loo Lin School of Medicine
Faculty of Medicine, Siriraj Hospital, Mahidol University
University of Houston
Tan Tock Seng Hospital
Baylor St. Luke's Medical Center
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Sep-2018
Citation: Clinical Pharmacology and Therapeutics. Vol.104, No.3 (2018), 534-538
Abstract: © 2017 American Society for Clinical Pharmacology and Therapeutics Polymyxin B is used as a last treatment resort for multidrug-resistant Gram-negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability. Four serial blood samples each were collected from 35 adult patients at steady state. The concentrations of individual polymyxin B components were analyzed using a validated liquid chromatography / tandem mass spectrometry assay and combined to derive total concentrations. A maximum likelihood expectation maximization approach was used to fit the data. Various demographic variables were investigated as potential covariates for clearance and volume of distribution (Vd) using linear regression analysis. A one-compartment model fit to the data satisfactorily (r2 = 0.96). The best-fit mean ± SD for clearance and Vd were 2.5 ± 1.1 L/h and 34.3 ± 16.4 L, respectively. Creatinine clearance was found to be a statistically significant covariate of clearance, but the magnitude was deemed clinically insignificant.
ISSN: 15326535
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.